87 related articles for article (PubMed ID: 20429264)
1. The effects of combined therapy of rheumatoid arthritis on the acute phase reactants.
Rexhepi S; Rexhepi M; Sahatçiu-Meka V; Pllana E; Dragusha G; Gashi M; Rexhepi B
Reumatizam; 2009; 56(2):77-80. PubMed ID: 20429264
[TBL] [Abstract][Full Text] [Related]
2. [Effect of combination therapy and nonsteroidal antirheumatic agents on acute phase reactants in patients with rheumatoid arthritis].
Berdnik-Gortan K; Bjelinski D
Reumatizam; 1999; 46(1):12-6. PubMed ID: 11552614
[TBL] [Abstract][Full Text] [Related]
3. Efficacy of triple DMARD therapy in patients with RA with suboptimal response to methotrexate.
O'Dell JR; Haire C; Erikson N; Drymalski W; Palmer W; Maloley P; Klassen LW; Wees S; Moore GF
J Rheumatol Suppl; 1996 Mar; 44():72-4. PubMed ID: 8833058
[TBL] [Abstract][Full Text] [Related]
4. [Comparison of efficacy and tolerability of triple combination therapy (methotrexate + sulfasalazine + hydroxychloroquine) with methotrexate monotherapy in patients with rheumatoid arthritis].
Gubar' EE; Bochkova AG; Bunchuk NV
Ter Arkh; 2008; 80(5):25-30. PubMed ID: 18590110
[TBL] [Abstract][Full Text] [Related]
5. Rheumatoid factor, but not anti-cyclic citrullinated peptide antibodies, is modulated by infliximab treatment in rheumatoid arthritis.
De Rycke L; Verhelst X; Kruithof E; Van den Bosch F; Hoffman IE; Veys EM; De Keyser F
Ann Rheum Dis; 2005 Feb; 64(2):299-302. PubMed ID: 15166003
[TBL] [Abstract][Full Text] [Related]
6. Ocrelizumab, a humanized anti-CD20 monoclonal antibody, in the treatment of patients with rheumatoid arthritis: a phase I/II randomized, blinded, placebo-controlled, dose-ranging study.
Genovese MC; Kaine JL; Lowenstein MB; Del Giudice J; Baldassare A; Schechtman J; Fudman E; Kohen M; Gujrathi S; Trapp RG; Sweiss NJ; Spaniolo G; Dummer W;
Arthritis Rheum; 2008 Sep; 58(9):2652-61. PubMed ID: 18759293
[TBL] [Abstract][Full Text] [Related]
7. Serum matrix metalloproteinase 3 levels during treatment with sulfasalazine or combination of methotrexate and sulfasalazine in patients with early rheumatoid arthritis.
Posthumus MD; Limburg PC; Westra J; van Leeuwen MA; van Rijswijk MH
J Rheumatol; 2002 May; 29(5):883-9. PubMed ID: 12022344
[TBL] [Abstract][Full Text] [Related]
8. Longterm combination therapy of refractory and destructive rheumatoid arthritis with methotrexate (MTX) and intramuscular gold or other disease modifying antirheumatic drugs compared to MTX monotherapy.
Rau R; Schleusser B; Herborn G; Karger T
J Rheumatol; 1998 Aug; 25(8):1485-92. PubMed ID: 9712088
[TBL] [Abstract][Full Text] [Related]
9. Impact of initial aggressive drug treatment with a combination of disease-modifying antirheumatic drugs on the development of work disability in early rheumatoid arthritis: a five-year randomized followup trial.
Puolakka K; Kautiainen H; Möttönen T; Hannonen P; Korpela M; Julkunen H; Luukkainen R; Vuori K; Paimela L; Blåfield H; Hakala M; Leirisalo-Repo M
Arthritis Rheum; 2004 Jan; 50(1):55-62. PubMed ID: 14730599
[TBL] [Abstract][Full Text] [Related]
10. Treatment of rheumatoid arthritis with methotrexate and hydroxychloroquine, methotrexate and sulfasalazine, or a combination of the three medications: results of a two-year, randomized, double-blind, placebo-controlled trial.
O'Dell JR; Leff R; Paulsen G; Haire C; Mallek J; Eckhoff PJ; Fernandez A; Blakely K; Wees S; Stoner J; Hadley S; Felt J; Palmer W; Waytz P; Churchill M; Klassen L; Moore G
Arthritis Rheum; 2002 May; 46(5):1164-70. PubMed ID: 12115219
[TBL] [Abstract][Full Text] [Related]
11. [Combined basic therapy of rheumatoid arthritis with methotrexate and plaquenil].
Sergiets NA; Erov NK
Ter Arkh; 2009; 81(6):34-7. PubMed ID: 19663190
[TBL] [Abstract][Full Text] [Related]
12. Tight control and intensified COBRA combination treatment in early rheumatoid arthritis: 90% remission in a pilot trial.
van Tuyl LH; Lems WF; Voskuyl AE; Kerstens PJ; Garnero P; Dijkmans BA; Boers M
Ann Rheum Dis; 2008 Nov; 67(11):1574-7. PubMed ID: 18625629
[TBL] [Abstract][Full Text] [Related]
13. [The effect of an antimalarial agent (chloroquine) on acute phase reactants in patients with rheumatoid arthritis].
Jajić Z; Vuksic D; Jajić I
Reumatizam; 1994; 41(2):5-7. PubMed ID: 8693197
[TBL] [Abstract][Full Text] [Related]
14. [Three joints swollen, blood sedimentation increased. Methotrexate to be given immediately?].
Burmester GR
MMW Fortschr Med; 2004 Sep; 146(37):10. PubMed ID: 15887693
[No Abstract] [Full Text] [Related]
15. Increase of bone mineral density and anabolic variables in patients with rheumatoid arthritis resistant to methotrexate after cyclosporin A therapy.
Ferraccioli G; Casatta L; Bartoli E
J Rheumatol; 1996 Sep; 23(9):1539-42. PubMed ID: 8877921
[TBL] [Abstract][Full Text] [Related]
16. Short term effects of low dose methotrexate on the acute phase reaction in patients with rheumatoid arthritis.
Segal R; Caspi D; Tishler M; Wigler I; Yaron M
J Rheumatol; 1989 Jul; 16(7):914-7. PubMed ID: 2504917
[TBL] [Abstract][Full Text] [Related]
17. Response-driven combination therapy with conventional disease-modifying antirheumatic drugs can achieve high response rates in early rheumatoid arthritis with minimal glucocorticoid and nonsteroidal anti-inflammatory drug use.
Proudman SM; Keen HI; Stamp LK; Lee AT; Goldblatt F; Ayres OC; Rischmueller M; James MJ; Hill CL; Caughey GE; Cleland LG
Semin Arthritis Rheum; 2007 Oct; 37(2):99-111. PubMed ID: 17391739
[TBL] [Abstract][Full Text] [Related]
18. Etanercept added to background methotrexate therapy in patients with rheumatoid arthritis: continued observations.
Kremer JM; Weinblatt ME; Bankhurst AD; Bulpitt KJ; Fleischmann RM; Jackson CG; Atkins KM; Feng A; Burge DJ
Arthritis Rheum; 2003 Jun; 48(6):1493-9. PubMed ID: 12794815
[TBL] [Abstract][Full Text] [Related]
19. Unaltered etanercept pharmacokinetics with concurrent methotrexate in patients with rheumatoid arthritis.
Zhou H; Mayer PR; Wajdula J; Fatenejad S
J Clin Pharmacol; 2004 Nov; 44(11):1235-43. PubMed ID: 15496641
[TBL] [Abstract][Full Text] [Related]
20. Progression of joint damage in early rheumatoid arthritis: association with HLA-DRB1, rheumatoid factor, and anti-citrullinated protein antibodies in relation to different treatment strategies.
de Vries-Bouwstra JK; Goekoop-Ruiterman YP; Verpoort KN; Schreuder GM; Ewals JA; Terwiel JP; Ronday HK; Kerstens PJ; Toes RE; de Vries RR; Breedveld FC; Dijkmans BA; Huizinga TW; Allaart CF
Arthritis Rheum; 2008 May; 58(5):1293-8. PubMed ID: 18438829
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
